Ascent Group LLC Has $740,000 Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Ascent Group LLC trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 5.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,081 shares of the financial services provider’s stock after selling 308 shares during the period. Ascent Group LLC’s holdings in iShares Biotechnology ETF were worth $740,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF in the third quarter worth $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF in the third quarter valued at about $30,000. Bbjs Financial Advisors LLC bought a new stake in iShares Biotechnology ETF during the second quarter worth about $31,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF during the third quarter valued at approximately $36,000. Finally, Voisard Asset Management Group Inc. acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $59,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $140.00 on Wednesday. iShares Biotechnology ETF has a 1-year low of $121.84 and a 1-year high of $150.57. The firm has a fifty day simple moving average of $142.63 and a 200 day simple moving average of $142.12.

iShares Biotechnology ETF Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.